An innovative treatment conducted by the NHS has yielded “groundbreaking” results, showcasing the ability to induce remission in patients suffering from lupus, as demonstrated by trials in the UK.
In a milestone development for the UK, individuals with severe lupus have undergone treatment using CAR T-cell therapy, a technique that experts believe could have applications beyond lupus, possibly benefiting conditions like multiple sclerosis. This therapy, requiring only a single administration, has the potential to transform treatment approaches, potentially eliminating the necessity for lifelong medication. Katie Tinkler, one of the initial recipients of this treatment, described the stark contrast in her life before and after the therapy as “like night and day.”
Lupus, characterized as a chronic autoimmune ailment, involves the immune system attacking healthy tissues, leading to widespread inflammation and organ damage, affecting organs such as the kidneys, lungs, and heart.
CAR T-cell therapy functions by genetically modifying cells to enable the body’s immune system to identify and eliminate problematic cells. Historically used primarily for cancer patients within the NHS, this therapy was trialed with lupus patients at University College London Hospitals NHS Foundation Trust (UCLH) and University College London (UCL), resulting in remission for five out of six patients with severe lupus within a few months of receiving CAR-T.
Katie Tinkler recounted her struggles with severe lupus, which forced her to leave her job as a fitness instructor due to excruciating pain and fatigue. The disease caused her to endure swollen joints, kidney damage nearing dialysis necessity, lung and heart issues, and a propensity for blood clot formation. Suffering from sepsis and multi-organ failure, she was previously in a coma in intensive care. Thanks to CAR-T treatment received at UCLH, the 52-year-old from Guildford, Surrey, married with three children, is now in remission.
Reflecting on her transformative experience, Katie shared how she can now engage in activities previously hindered by her condition, such as going on a ski trip after a decade and dancing at her daughter’s wedding. She has successfully discontinued all steroid treatments and other medications, now only taking two daily tablets for blood clot prevention and blood pressure control. Katie described the significant improvement in her quality of life, stressing the remarkable progress achieved within the past two years.
Approximately 69,000 individuals in the UK are estimated to be affected by lupus, a disease predominantly impacting women. The recent study enrolled nine patients with active severe lupus who had not responded to conventional treatments. Of these, six patients received a lower dose of CAR-T, while three received a higher dose for comparison purposes.
Post-infusion, patients exhibited robust expansion of CAR-T cells and significant reduction in problematic B cells. Over time, B cells began to return, typically within three to six months, but predominantly in early-stage forms, less likely to trigger lupus-related issues.
Researchers highlighted that the outcomes suggest the therapy may facilitate an “immune reset,” rather than merely suppressing the immune system, a critical aspect in treating autoimmune disorders.
Professor Karl Peggs, director of UCLH’s biomedical research center, emphasized the potential for CAR-T therapy to offer a curative pathway, albeit stressing the necessity for larger-scale studies. He hailed the findings as groundbreaking, offering renewed hope for individuals grappling with lupus and hinting at the prospect of a cure no longer being beyond reach.